LB PHARMACEUTICALS INC (LBRX) Stock Fundamental Analysis

NASDAQ:LBRX • US50180M1080

23.34 USD
-1.01 (-4.15%)
At close: Feb 13, 2026
23.34 USD
0 (0%)
After Hours: 2/13/2026, 8:21:21 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

LBRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. LBRX has a great financial health rating, but its profitability evaluates not so good. LBRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year LBRX has reported negative net income.
LBRX Yearly Net Income VS EBIT VS OCF VS FCFLBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -19.67%, LBRX is in the better half of the industry, outperforming 61.26% of the companies in the same industry.
  • With a decent Return On Equity value of -20.34%, LBRX is doing good in the industry, outperforming 68.59% of the companies in the same industry.
Industry RankSector Rank
ROA -19.67%
ROE -20.34%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LBRX Yearly ROA, ROE, ROICLBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 -100 -200 -300

1.3 Margins

  • LBRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LBRX Yearly Profit, Operating, Gross MarginsLBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • LBRX has about the same amout of shares outstanding than it did 1 year ago.
  • LBRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LBRX Yearly Shares OutstandingLBRX Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 5M 10M 15M 20M
LBRX Yearly Total Debt VS Total AssetsLBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • An Altman-Z score of 33.64 indicates that LBRX is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of LBRX (33.64) is better than 94.76% of its industry peers.
  • LBRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 33.64
ROIC/WACCN/A
WACCN/A
LBRX Yearly LT Debt VS Equity VS FCFLBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

  • LBRX has a Current Ratio of 47.60. This indicates that LBRX is financially healthy and has no problem in meeting its short term obligations.
  • LBRX has a Current ratio of 47.60. This is amongst the best in the industry. LBRX outperforms 98.95% of its industry peers.
  • A Quick Ratio of 47.60 indicates that LBRX has no problem at all paying its short term obligations.
  • The Quick ratio of LBRX (47.60) is better than 98.95% of its industry peers.
Industry RankSector Rank
Current Ratio 47.6
Quick Ratio 47.6
LBRX Yearly Current Assets VS Current LiabilitesLBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for LBRX have decreased strongly by -905.62% in the last year.
EPS 1Y (TTM)-905.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • LBRX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -13.96% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-31.96%
EPS Next 2Y-21.4%
EPS Next 3Y-13.96%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LBRX Yearly EPS VS EstimatesLBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • LBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LBRX Price Earnings VS Forward Price EarningsLBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LBRX Per share dataLBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as LBRX's earnings are expected to decrease with -13.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.4%
EPS Next 3Y-13.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for LBRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LB PHARMACEUTICALS INC

NASDAQ:LBRX (2/13/2026, 8:21:21 PM)

After market: 23.34 0 (0%)

23.34

-1.01 (-4.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners87.91%
Inst Owner Change16.54%
Ins Owners0.31%
Ins Owner Change0%
Market Cap590.50M
Revenue(TTM)N/A
Net Income(TTM)-63.10M
Analysts86
Price Target43.35 (85.73%)
Short Float %7.29%
Short Ratio5.61
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.27%
PT rev (3m)-8.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-38.31%
EPS NY rev (3m)-18.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.9
P/tB 1.9
EV/EBITDA N/A
EPS(TTM)-2.81
EYN/A
EPS(NY)-4.14
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS12.26
TBVpS12.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.67%
ROE -20.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 47.6
Quick Ratio 47.6
Altman-Z 33.64
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-905.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-31.96%
EPS Next 2Y-21.4%
EPS Next 3Y-13.96%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-469.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-344.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-338.66%
OCF growth 3YN/A
OCF growth 5YN/A

LB PHARMACEUTICALS INC / LBRX FAQ

What is the fundamental rating for LBRX stock?

ChartMill assigns a fundamental rating of 3 / 10 to LBRX.


Can you provide the valuation status for LB PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to LB PHARMACEUTICALS INC (LBRX). This can be considered as Overvalued.


What is the profitability of LBRX stock?

LB PHARMACEUTICALS INC (LBRX) has a profitability rating of 1 / 10.


How financially healthy is LB PHARMACEUTICALS INC?

The financial health rating of LB PHARMACEUTICALS INC (LBRX) is 9 / 10.